scholarly journals The effect of hormone replacement therapy on the expression of the alkaline phosphatase gene (ALPL) within the mucosal epithelium of the cheek and in peripheral blood lymphocytes

2014 ◽  
Vol 27 (2) ◽  
pp. 92-96 ◽  
Author(s):  
Mansur Rahnama ◽  
Michal Lobacz ◽  
Anna Szyszkowska ◽  
Grzegorz Trybek ◽  
Maryla Kozicka-Czupkallo
Keyword(s):  
Alkaline Phosphatase ◽  
Hormone Replacement Therapy ◽  
Bone Formation ◽  
Replacement Therapy ◽  
Peripheral Blood ◽  
Bone Mineralization ◽  
Hormone Replacement ◽  
Peripheral Blood Lymphocytes ◽  
Mucosal Epithelium ◽  
Osteoblast Activity

Abstract In adult life, proper bone metabolism requires efficient regulation of bone formation and resorption processes. Bone turnover markers allow for assessing the rate of bone formation and resorption processes. In menopausal period, female patients experience gradual reduction in blood estradiol levels. The deficit of estrogens leads to enhanced osteoclastogenesis and bone resorption. Alkaline phosphatase (ALP) is a membranebound enzyme that stimulates the osteoblast activity and bone mineralization. It is synthesized by osteoblasts and incorporated into the newly formed bone tissue. The produced enzyme stimulates the osteoblast activity and bone mineralization. The goal of this study is to determine the effect of hormone replacement therapy in postmenopausal women on the expression of alkaline phosphatase gene (ALPL) within the mucosal epithelium of the cheek and in peripheral blood lymphocytes. The studies show that hormone replacement therapy has no significant effect on the increase in ALPL expression within the mucosal epithelium of the cheek. Only in women having undergone ovarectomy (OV), the epithelial ALPL expression level was higher than in the remaining groups.

scholarly journals Analysis of the Influence of Hormone Replacement Therapy on Osteocalcin Gene Expression in Postmenopausal Women

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Mansur Rahnama ◽  
Izabela Jastrzębska-Jamrogiewicz ◽  
Rafał Jamrogiewicz ◽  
Grzegorz Trybek
Keyword(s):  
Gene Expression ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Bone Metabolism ◽  
Postmenopausal Women ◽  
Bone Mineralization ◽  
Hormone Replacement ◽  
Peripheral Blood Lymphocytes ◽  
Local Bone ◽  
Osteocalcin Gene

Background.Osteocalcin (OC) contributes to the process of bone mineralization. Present study was designed to investigate the changes in OC gene expression of postmenopausal women treated with hormone replacement therapy (HRT). Study was also designed to evaluate OC gene expression in cells which are not part of connective tissue.Material and Methods.Research was carried out on 30 postmenopausal women not treated and 30 treated with HRT. Examination of OC gene expression was conducted on peripheral blood lymphocytes (PBL) and buccal epithelial lining (BEL). Densitometry was conducted on femur and mandible.Results.Tests revealed OC gene expression in BEL and PBL. BMD was higher in groups treated with HRT. Assessment of correlation between the OC gene expression in BEL and BMD of mandible revealed significant positive relation.Conclusions.OC gene expression can be stated BEL and PBL. Analysis of correlation between OC gene expression in oral cavity and mandible BMD showed significant correlation between local OC expression and local bone metabolism. The relation between OC gene expression and bone metabolism is complex and further research is needed to clear all of the uncertainties.

scholarly journals Development and Evaluation of Three Immunofluorometric Assays That Measure Different Forms of Osteocalcin in Serum

2000 ◽  
Vol 46 (3) ◽  
pp. 332-337 ◽  
Author(s):  
Sanna-Maria Käkönen ◽  
Jukka Hellman ◽  
Matti Karp ◽  
Pirjo Laaksonen ◽  
Karl J Obrant ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Hormone Replacement Therapy ◽  
Bone Formation ◽  
Diurnal Variation ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Control Group ◽  
Plasma Samples ◽  
Edta Plasma ◽  
Human Osteocalcin

Abstract Background: Circulating human osteocalcin (hOC) has been used as a marker of bone formation. Our aim was to validate three immunofluorometric assays (IFMAs), measuring different forms of hOC. Methods: The two-site IFMAs were based on previously characterized monoclonal antibodies. Assay 2 recognized intact hOC, assays 4 and 9 measured the NH2-terminal mid-fragment and the intact hOC. In addition, assay 9 required hOC to be γ-carboxylated. Results: A 76–79% increase of serum immunoreactive hOC was found in the postmenopausal group compared with the premenopausal group with all IFMAs. With EDTA-plasma samples, the observed increases were lower (49–65%). The hOC concentration in the postmenopausal group receiving hormone replacement therapy was 42–44% lower than that in the postmenopausal control group in both serum and EDTA-plasma samples. The depressed carboxylation in warfarin-treated patients was accompanied by lower results in assay 9. The ratio of assay 9 to assay 4 totally discriminated the warfarin-treated patients from the controls. Assay 9 showed the smallest decreases in measured hOC after storage of serum or plasma for 4 weeks at 4 °C, followed by assay 4 and assay 2. Results from the last assay were <17% of their initial values after 4 weeks of storage. No diurnal variation was observed with assay 9 as opposed to the two other IFMAs. Conclusion: The three assays with their distinct specificity profiles (intact vs fragmented and carboxylated vs decarboxylated hOC) may provide valuable tools for investigating the significance of different hOC forms in various bone-related diseases.

Markers of bone remodeling in patients with surgical menopause undergoing hormone replacement therapy with Divigel

2021 ◽  
Vol 50 (3) ◽  
pp. 70-75
Author(s):  
S. V. Yureneva ◽  
V. P. Smetnik ◽  
N. V. Lyubimova ◽  
V. M. Abaev
Keyword(s):  
Alkaline Phosphatase ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Bone Tissue ◽  
Bone Remodeling ◽  
Hormone Replacement ◽  
Hormonal Replacement Therapy ◽  
Mineral Density ◽  
Hormonal Replacement ◽  
Surgical Menopause

Twenty women with surgical menopause, 40-50 years of age, received hormonal replacement therapy with transdermic preparation Divigel during 24 months. On the background of therapy with Divigel we witnessed normalization of indeces of osteal remodelingconsiderable decrease pyridinoline and deoxypyridinoline, and elevation of alkaline phosphatase. Mineral density of bone tissue in the group of patients with surgical menopause waslowerin comparison with control (p0,01). Divigeltumedto exertprotective influence on the bone tissue inpatients with osteoporosis irrespective о f duration о f surgical menopause by the beginning of therapy.

Sign in / Sign up

Export Citation Format

Share Document